Nuvalent, Inc.

We’re excited to share the clinical study designs of our ALKAZAR Phase 3 trial of neladalkib and HEROEX-1 Phase 1 trial of NVL-330 in two “Trials in Progress” posters at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting! Learn more: https://lnkd.in/gesz5UZG #ASCO2025

📣 The #NuCrew is hiring! We are on the lookout for a Senior Scientist, Translational Medicine! 👀 Learn more about this role and other new opportunities here: https://lnkd.in/e49ST_wW #NuTalent #hiring #biotech

Join Nuvalent CEO James Porter and CFO Alex Balcom, MBA, CPA this month at Stifel Financial Corp.'s 2025 Virtual Targeted Oncology Forum. Recordings of the webcast will be available on our website for 30 days. https://lnkd.in/evA4J_aX $NUVL #biotech #oncology

📊 Join us at the American Association for Cancer Research's 2025 Annual Meeting where we'll present new preclinical data further characterizing our ALK-selective inhibitor, neladalkib, and our ROS1-selective inhibitor, zidesamtinib! Learn more: https://lnkd.in/dSwkHBCR #AACR25 #biotech #Nuvalent

HOT JOB ALERT 🚨 Senior Manager, Clinical Operations🚨 Interested in joining the #NuCrew? Learn more about this role and other new opportunities here: https://lnkd.in/dNd6YC7k #NuTalent #hiring #biotech

We had the honor of hosting Scientific Advisor, Alice Shaw, MD, PhD for Nuvalent’s most recent NED Talk. The #NuCrew was inspired to learn more about the impact of Alice’s research in expanding treatment options for patients with oncogene-driven lung cancer and the importance of open collaboration among academic and industry researchers to fuel patient-focused innovation. #NEDTalk #NSCLC #Oncology

Join Nuvalent CEO James Porter and CFO Alex Balcom, MBA, CPA next month at TD Cowen's 45th Annual Health Care Conference in Boston. They'll also present at the Leerink Partners' Global Biopharma Conference 2025 and Barclays' Global Healthcare Conference 2025 in Miami. Recordings of the webcasts will be available on our website for 30 days. https://lnkd.in/eeTTbP7a $NUVL #biotech #oncology

Today we reported our Q4 2024 and end-of-year financial results, highlighting recent progress and reiterating key anticipated milestones, including:   📊 Topline pivotal data expected for both TKI pre-treated ROS1-positive and TKI pre-treated ALK-positive NSCLC populations in 2025 📅 First NDA submission planned for mid-year 2025 towards potential first approval in 2026 for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population 🔬 Development strategies in place for TKI-naïve populations 🌎 Implemented global EAPs for zidesamtinib and neladalkib Read our updates here: https://lnkd.in/eBeTEzPD

🔗 Connect with us at this week's International Association for the Study of Lung Cancer Targeted Therapies of Lung Cancer Meeting in Huntington Beach, CA.

📣 The #NuCrew is hiring! We are on the lookout for a Senior Manager, Quality Control! 👀 Learn more about this role and other new opportunities here: https://lnkd.in/eV7EPM-e #NuTalent #hiring #biotech